{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:15:09Z","timestamp":1793488509777,"version":"4.5.0"},"reference-count":170,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The number of elderly people with chronic inflammatory rheumatic diseases is increasing. This heterogeneous and comorbid population is at particular risk of cardiovascular, neoplastic, infectious and iatrogenic complications. The development of biotherapies has paved the way for innovative therapeutic strategies, which are associated with toxicities. In this review, we have focused on the scientific and therapeutic changes impacting the management of elderly patients affected by RA, SpA or PsA. A multidimensional health assessment resulting in an integrated therapeutic strategy was identified as a major research direction for improving the management of elderly patients.<\/jats:p>","DOI":"10.1093\/rheumatology\/key165","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T19:13:18Z","timestamp":1528744398000},"page":"748-764","source":"Crossref","is-referenced-by-count":45,"title":["Management of inflammatory rheumatic conditions in the elderly"],"prefix":"10.1093","volume":"58","author":[{"given":"Cl\u00e9ment","family":"Lahaye","sequence":"first","affiliation":[{"name":"CHU Clermont-Ferrand, Department of Rheumatology, H\u00f4pital Gabriel Montpied, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Tatar","sequence":"additional","affiliation":[{"name":"CHU Clermont-Ferrand, Department of Rheumatology, H\u00f4pital Gabriel Montpied, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Dubost","sequence":"additional","affiliation":[{"name":"CHU Clermont-Ferrand, Department of Rheumatology, H\u00f4pital Gabriel Montpied, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tournadre","sequence":"additional","affiliation":[{"name":"CHU Clermont-Ferrand, Department of Rheumatology, H\u00f4pital Gabriel Montpied, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Soubrier","sequence":"additional","affiliation":[{"name":"CHU Clermont-Ferrand, Department of Rheumatology, H\u00f4pital Gabriel Montpied, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"2019081609500867900_key165-B1","first-page":"1659","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2015","journal-title":"Lancet"},{"key":"2019081609500867900_key165-B2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging. An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"2019081609500867900_key165-B3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.coi.2009.05.023","article-title":"Immunosenescence: what does it mean to health outcomes in older adults?","volume":"21","author":"McElhaney","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"2019081609500867900_key165-B4","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.4065\/78.12.1564","article-title":"Principles of drug therapy for the elderly patient","volume":"78","author":"Bressler","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2019081609500867900_key165-B5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(02)07451-2","article-title":"Bias and causal associations in observational research","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"key":"2019081609500867900_key165-B6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jbspin.2010.04.004","article-title":"Elderly-onset rheumatoid arthritis","volume":"77","author":"Soubrier","year":"2010","journal-title":"Joint Bone Spine"},{"key":"2019081609500867900_key165-B7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/CMAMD.S4935","article-title":"Pattern of young and old onset rheumatoid arthritis (YORA and EORA) among a group of egyptian patients with rheumatoid arthritis","volume":"3","author":"El-Labban","year":"2010","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"2019081609500867900_key165-B8","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/rheumatology\/kew335","article-title":"Older age is associated with more MRI-detected inflammation in hand and foot joints","volume":"55","author":"Nieuwenhuis","year":"2016","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000164393","article-title":"Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease","volume":"55","author":"Chen","year":"2009","journal-title":"Gerontology"},{"key":"2019081609500867900_key165-B10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1365-2362.2012.02689.x","article-title":"Chronic inflammation as predictor of 1-year hospitalization and mortality in elderly population","volume":"42","author":"de Gonzalo-Calvo","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"2019081609500867900_key165-B11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/rheumatology\/ket399","article-title":"Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort","volume":"53","author":"Mueller","year":"2014","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B12","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar4540","article-title":"Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study","volume":"16","author":"Innala","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2019081609500867900_key165-B13","first-page":"256","article-title":"Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account","volume":"31","author":"Huscher","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2019081609500867900_key165-B14","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3899\/jrheum.160051","article-title":"Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD Study","volume":"43","author":"Sekiguchi","year":"2016","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jbspin.2015.09.010","article-title":"Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: the ESPOIR cohort","volume":"83","author":"Krams","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2019081609500867900_key165-B16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B18","first-page":"218","article-title":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis","volume":"22","year":"1995","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ard.2010.139212","article-title":"Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial","volume":"70","author":"Saevarsdottir","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00002512-200926050-00003","article-title":"Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment","volume":"26","author":"Alivernini","year":"2009","journal-title":"Drugs Aging"},{"key":"2019081609500867900_key165-B21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s13075-015-0895-8","article-title":"Half of U.K. patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study","volume":"17","author":"Black","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2019081609500867900_key165-B22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/acr.23185","article-title":"\u201cOfficial view\u201d on glucocorticoids in rheumatoid arthritis: a systematic review of international guidelines and consensus statements","volume":"69","author":"Palmowski","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.22688","article-title":"Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study","volume":"57","author":"Genevay","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2019081609500867900_key165-B24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/kep129","article-title":"Missed opportunities in the treatment of elderly patients with rheumatoid arthritis","volume":"48","author":"Radovits","year":"2009","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2019081609500867900_key165-B26","doi-asserted-by":"crossref","first-page":"416892","DOI":"10.1155\/2014\/416892","article-title":"Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry","volume":"2014","author":"Filippini","year":"2014","journal-title":"Biomed Res Int"},{"key":"2019081609500867900_key165-B27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-009-8142-1","article-title":"Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study","volume":"38","author":"Filippini","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"2019081609500867900_key165-B28","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-\u03b1 therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B29","first-page":"234","article-title":"Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis","volume":"33","author":"Bathon","year":"2006","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00002512-200724030-00005","article-title":"Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis","volume":"24","author":"Fleischmann","year":"2007","journal-title":"Drugs Aging"},{"key":"2019081609500867900_key165-B31","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/rheumatology\/kep291","article-title":"Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients","volume":"48","author":"K\u00f6ller","year":"2009","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B32","article-title":"Efficacy of etanercept in elderly patients with rheumatoid arthritis [abstract]","volume":"69 (suppl 10)","author":"Edwards","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500867900_key165-B33","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar4521","article-title":"Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients","volume":"16","author":"Wendler","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2019081609500867900_key165-B34","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/acr.22314","article-title":"Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology Registry","volume":"66","author":"Payet","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B35","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","article-title":"Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology\u2019s ORA registry","volume":"55","author":"Lahaye","year":"2016","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B36","article-title":"Being elderly is not a predictive factor of discontinuation of abatacept due to adverse events in rheumatoid arthritis patients with concomitant methotrexate: a retrospective observational study based on data from a Japanese Multicenter Registry Study [abstract]","volume":"69 (suppl 10)","author":"Takahashi","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500867900_key165-B37","article-title":"Analysis of the efficacy, safety and continuation rate of abatacept in elderly patients with rheumatoid arthritis [abstract]","volume":"69 (suppl 10)","author":"Matsuda","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500867900_key165-B38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbspin.2014.07.010","article-title":"Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis","volume":"82","author":"Pers","year":"2015","journal-title":"Joint Bone Spine"},{"key":"2019081609500867900_key165-B39","first-page":"390","article-title":"Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2019081609500867900_key165-B40","doi-asserted-by":"crossref","first-page":"e000546","DOI":"10.1136\/rmdopen-2017-000546","article-title":"Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"2019081609500867900_key165-B41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12891-016-1038-3","article-title":"The challenging interplay between rheumatoid arthritis, ageing and comorbidities","volume":"17","author":"van Onna","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"2019081609500867900_key165-B42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.21812","article-title":"Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00002512-200825100-00007","article-title":"Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Qu\u00e9bec, Canada","volume":"25","author":"Bernatsky","year":"2008","journal-title":"Drugs Aging"},{"key":"2019081609500867900_key165-B44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study","volume":"127","author":"Alarc\u00f3n","year":"1997","journal-title":"Ann Intern Med"},{"key":"2019081609500867900_key165-B45","first-page":"1727","article-title":"Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis","volume":"31","author":"Kent","year":"2004","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B46","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/art.39647","article-title":"Changes in body mass related to the initiation of disease-modifying therapies in rheumatoid arthritis","volume":"68","author":"Baker","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500867900_key165-B47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12891-016-1185-6","article-title":"Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis","volume":"17","author":"Cho","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"2019081609500867900_key165-B48","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3899\/jrheum.160012","article-title":"Safety of biologic agents in elderly patients with rheumatoid arthritis","volume":"43","author":"Murota","year":"2016","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B49","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.20550","article-title":"Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis","volume":"63","author":"Kawai","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B50","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/rheumatology\/ker281","article-title":"Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry","volume":"50","author":"Busquets","year":"2011","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B51","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3899\/jrheum.101009","article-title":"Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety","volume":"38","author":"Komano","year":"2011","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MD.0b013e318211106a","article-title":"TNF-\u03b1 antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis","volume":"90","author":"Lane","year":"2011","journal-title":"Medicine"},{"key":"2019081609500867900_key165-B54","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/acr.21805","article-title":"Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B55","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2019081609500867900_key165-B56","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-016-3631-z","article-title":"Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis","volume":"37","author":"Kawashima","year":"2017","journal-title":"Rheumatol Int"},{"key":"2019081609500867900_key165-B57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/pds.3238","article-title":"Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?","volume":"21","author":"Toh","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019081609500867900_key165-B58","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2019081609500867900_key165-B59","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/ard.2005.051144","article-title":"Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?","volume":"65","author":"Tutuncu","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B60","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor \u03b1 therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2019081609500867900_key165-B61","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019081609500867900_key165-B62","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/ard.2008.094730","article-title":"Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis","volume":"68","author":"Radovits","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B63","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B64","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/pds.3354","article-title":"Association between anti-TNF-\u03b1 therapy and all-cause mortality","volume":"21","author":"Herrinton","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019081609500867900_key165-B65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides \u2013 a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B66","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13075-014-0449-5","article-title":"The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study","volume":"16","author":"Wu","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2019081609500867900_key165-B67","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B68","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s10067-013-2387-z","article-title":"Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area","volume":"33","author":"Kim","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2019081609500867900_key165-B69","doi-asserted-by":"crossref","first-page":"e0178035","DOI":"10.1371\/journal.pone.0178035","article-title":"The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan","volume":"12","author":"Lim","year":"2017","journal-title":"PLoS One"},{"key":"2019081609500867900_key165-B70","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"J Am Med Assoc"},{"key":"2019081609500867900_key165-B71","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2019081609500867900_key165-B72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500867900_key165-B73","first-page":"893","article-title":"Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study","volume":"34","author":"Vassilopoulos","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2019081609500867900_key165-B74","doi-asserted-by":"crossref","first-page":"e000546","DOI":"10.1136\/rmdopen-2017-000546","article-title":"Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"2019081609500867900_key165-B75","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2019081609500867900_key165-B76","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"2019081609500867900_key165-B77","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/acr.22997","article-title":"Impact of rheumatoid arthritis on the mortality of elderly patients who develop cancer: a population-based study","volume":"69","author":"Nayak","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/art.30653","article-title":"Observational studies on the risk of cancer associated with TNF-Inhibitors in RA: a review of their methodologies and results","volume":"64","author":"Solomon","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2019081609500867900_key165-B79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor \u03b1 inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2019081609500867900_key165-B80","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019081609500867900_key165-B81","doi-asserted-by":"crossref","first-page":"i262","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"key":"2019081609500867900_key165-B82","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","article-title":"Rheumatoid arthritis and cardiovascular disease","volume":"166","author":"Crowson","year":"2013","journal-title":"Am Heart J"},{"key":"2019081609500867900_key165-B83","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ard.2010.143396","article-title":"The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study","volume":"70","author":"Lindhardsen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B84","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B85","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","article-title":"Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis","volume":"156","author":"Setoguchi","year":"2008","journal-title":"Am Heart J"},{"key":"2019081609500867900_key165-B86","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","article-title":"Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis","volume":"75","author":"Zhang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B87","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2019081609500867900_key165-B88","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/rheumatology\/kew344","article-title":"Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies","volume":"55","author":"Bijlsma","year":"2016","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B89","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B91","first-page":"1214","article-title":"Late onset peripheral spondyloarthropathy","volume":"16","author":"Dubost","year":"1989","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B92","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/11315970-000000000-00000","article-title":"Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies","volume":"27","author":"Toussirot","year":"2010","journal-title":"Drugs Aging"},{"key":"2019081609500867900_key165-B93","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3899\/jrheum.111082","article-title":"Clinical features of late-onset ankylosing spondylitis: comparison with early-onset disease","volume":"39","author":"Montilla","year":"2012","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B94","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B95","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.58.4.226","article-title":"Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease","volume":"58","author":"Punzi","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B96","doi-asserted-by":"crossref","first-page":"e7833","DOI":"10.1097\/MD.0000000000007833","article-title":"Characteristics of Turkish patients with elderly onset psoriatic arthritis: a retrospective cohort study","volume":"96","author":"Kobak","year":"2017","journal-title":"Medicine"},{"key":"2019081609500867900_key165-B97","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.120239","article-title":"Mortality and causes of death in psoriatic arthritis","volume":"89","author":"Arumugam","year":"2012","journal-title":"J Rheumatol Suppl"},{"key":"2019081609500867900_key165-B98","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00296-016-3617-x","article-title":"High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: a study based on carotid ultrasound","volume":"37","author":"Ib\u00e1\u00f1ez-Bosch","year":"2017","journal-title":"Rheumatol Int"},{"key":"2019081609500867900_key165-B99","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.semarthrit.2014.10.007","article-title":"Cardiovascular events in ankylosing spondylitis: an updated meta-analysis","volume":"44","author":"Mathieu","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2019081609500867900_key165-B100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2011.09.006","article-title":"Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists","volume":"67","author":"Parsi","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2019081609500867900_key165-B101","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2011.06.035","article-title":"Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis","volume":"67","author":"Kimball","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2019081609500867900_key165-B102","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RHU.0000000000000364","article-title":"Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis","volume":"22","author":"Hagberg","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"2019081609500867900_key165-B103","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40266-014-0156-6","article-title":"Managing moderate-to-severe psoriasis in the elderly","volume":"31","author":"Balato","year":"2014","journal-title":"Drugs Aging"},{"key":"2019081609500867900_key165-B104","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A comparison of malignancy incidence among psoriatic and rheumatoid arthritis patients in a large US cohort","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500867900_key165-B105","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2016.11.046","article-title":"Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures","volume":"76","author":"Kathuria","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2019081609500867900_key165-B106","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaad.2010.05.014","article-title":"Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation","volume":"65","author":"Grozdev","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2019081609500867900_key165-B107","doi-asserted-by":"crossref","first-page":"367475","DOI":"10.1155\/2012\/367475","article-title":"The safety of systemic treatments that can be used for geriatric psoriasis patients: a review","volume":"2012","author":"Wong","year":"2012","journal-title":"Dermatol Res Pract"},{"key":"2019081609500867900_key165-B108","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2340\/00015555-1719","article-title":"Efficacy and safety of systemic treatments for psoriasis in elderly patients","volume":"94","author":"Piaserico","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"2019081609500867900_key165-B109","first-page":"846","article-title":"Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis","volume":"14","author":"Garber","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"2019081609500867900_key165-B110","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","article-title":"Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis","volume":"63","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2019081609500867900_key165-B111","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2006.02.010","article-title":"Etanercept for the treatment of psoriasis in the elderly","volume":"55","author":"Militello","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2019081609500867900_key165-B112","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3899\/jrheum.110763","article-title":"Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-\u03b1 blockers","volume":"39","author":"Iervolino","year":"2012","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B113","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1080\/14740338.2016.1226279","article-title":"Efficacy and safety of infliximab in psoriatic patients over the age of 65","volume":"15","author":"Chiricozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2019081609500867900_key165-B114","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000345623","article-title":"Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study","volume":"225","author":"Esposito","year":"2012","journal-title":"Dermatology"},{"key":"2019081609500867900_key165-B115","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/jdv.12688","article-title":"Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry","volume":"29","author":"Medina","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2019081609500867900_key165-B116","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2008.08891.x","article-title":"Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians","volume":"160","author":"Perlmutter","year":"2009","journal-title":"Br J Dermatol"},{"key":"2019081609500867900_key165-B117","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1346-8138.12653","article-title":"Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis","volume":"41","author":"Hayashi","year":"2014","journal-title":"J Dermatol"},{"key":"2019081609500867900_key165-B118","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ced.12850","article-title":"Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period","volume":"41","author":"Megna","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"2019081609500867900_key165-B119","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2019081609500867900_key165-B120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B121","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015. Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500867900_key165-B122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B123","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br J Dermatol"},{"key":"2019081609500867900_key165-B124","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","article-title":"Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis","volume":"52","author":"Ranganath","year":"2013","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40744-015-0021-z","article-title":"Biologics prescribing for rheumatoid arthritis in older patients: a single-center retrospective cross-sectional study","volume":"2","author":"Morsley","year":"2015","journal-title":"Rheumatol Ther"},{"key":"2019081609500867900_key165-B126","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jbspin.2012.12.002","article-title":"Vascular effects of nonsteroidal antiinflammatory drugs","volume":"80","author":"Soubrier","year":"2013","journal-title":"Joint Bone Spine"},{"key":"2019081609500867900_key165-B127"},{"key":"2019081609500867900_key165-B128","doi-asserted-by":"crossref","first-page":"937.e9","DOI":"10.1016\/j.amjmed.2011.11.014","article-title":"Time trends in medication use and expenditures in older patients with rheumatoid arthritis","volume":"125","author":"Harrold","year":"2012","journal-title":"Am J Med"},{"key":"2019081609500867900_key165-B129","first-page":"301","article-title":"Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry","volume":"20","author":"Martin","year":"2014","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"2019081609500867900_key165-B130","doi-asserted-by":"crossref","first-page":"e002468","DOI":"10.1136\/bmjopen-2012-002468","article-title":"A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers","volume":"3","author":"Ng","year":"2013","journal-title":"BMJ Open"},{"key":"2019081609500867900_key165-B131","article-title":"Biologic DMARD prescribing patterns in elderly patients with rheumatoid arthritis [abstract]","volume":"69 (suppl 10)","author":"Jones","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500867900_key165-B132","article-title":"Predictors of earlier biologic initiation among patients with rheumatoid arthritis starting methotrexate [abstract]","volume":"69 (suppl 10)","author":"George","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500867900_key165-B133","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/rheumatology\/kew048","article-title":"Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD","volume":"55","author":"Putrik","year":"2016","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B134","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/acr.22244","article-title":"Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study","volume":"66","author":"Yelin","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B135","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1586\/eci.12.23","article-title":"Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature","volume":"8","author":"van den Bemt","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"2019081609500867900_key165-B136","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cger.2012.01.002","article-title":"Polypharmacy, adverse drug reactions, and geriatric syndromes","volume":"28","author":"Shah","year":"2012","journal-title":"Clin Geriatr Med"},{"key":"2019081609500867900_key165-B137","first-page":"857","article-title":"Methods to reduce prescribing errors in elderly patients with multimorbidity","volume":"11","author":"Lavan","year":"2016","journal-title":"Clin Interv Aging"},{"key":"2019081609500867900_key165-B138","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s11136-015-1213-2","article-title":"Frailty predicts trajectories of quality of life over time among British community-dwelling older people","volume":"25","author":"Kojima","year":"2016","journal-title":"Qual Life Res"},{"key":"2019081609500867900_key165-B139","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/psyg.12179","article-title":"Exploration of the importance of geriatric frailty on health-related quality of life","volume":"16","author":"Lee","year":"2016","journal-title":"Psychogeriatrics"},{"key":"2019081609500867900_key165-B140","doi-asserted-by":"crossref","first-page":"e0175868","DOI":"10.1371\/journal.pone.0175868","article-title":"Predictors of falls and mortality among elderly adults with traumatic brain injury: a nationwide, population-based study","volume":"12","author":"Fu","year":"2017","journal-title":"PLoS One"},{"key":"2019081609500867900_key165-B141","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/bcp.12709","article-title":"The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population","volume":"80","author":"Yun","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2019081609500867900_key165-B142","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.57.2.110","article-title":"Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients","volume":"57","author":"Bressolle","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B143","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/ard.2008.088237","article-title":"Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?","volume":"68","author":"Hider","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B144","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B145","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/1756-185X.12348","article-title":"Risk factors of adverse events during treatment in elderly patients with rheumatoid arthritis: an observational study","volume":"20","author":"Iwanaga","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2019081609500867900_key165-B146","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab","volume":"74","author":"Listing","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B147","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ggi.12231","article-title":"Effects of comprehensive geriatric assessment-based individually targeted interventions on mobility of pre-frail and frail community-dwelling older people","volume":"15","author":"Tikkanen","year":"2015","journal-title":"Geriatr Gerontol Int"},{"key":"2019081609500867900_key165-B148","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/rheumatology\/ket169","article-title":"The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis","volume":"52","author":"Matcham","year":"2013","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B149","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11136-016-1387-2","article-title":"Depression risk in patients with late-onset rheumatoid arthritis in Germany","volume":"26","author":"Drosselmeyer","year":"2017","journal-title":"Qual Life Res"},{"key":"2019081609500867900_key165-B150","first-page":"1013","article-title":"Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis","volume":"32","author":"Ang","year":"2005","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B151","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/kew502","article-title":"Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis","volume":"56","author":"Ogdie","year":"2017","journal-title":"Rheumatology"},{"key":"2019081609500867900_key165-B152","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2169\/internalmedicine.56.8039","article-title":"Clinical characteristics of rheumatoid arthritis patients achieving functional remission with six months of biological DMARDs treatment","volume":"56","author":"Miwa","year":"2017","journal-title":"Intern Med"},{"key":"2019081609500867900_key165-B153","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","article-title":"Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study","volume":"76","author":"Michelsen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019081609500867900_key165-B154","first-page":"CD008920","article-title":"Antidepressants for pain management in rheumatoid arthritis","volume":"11","author":"Richards","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2019081609500867900_key165-B155","doi-asserted-by":"crossref","first-page":"e0184666","DOI":"10.1371\/journal.pone.0184666","article-title":"Non-pharmacological treatment for depressed older patients in primary care: a systematic review and meta-analysis","volume":"12","author":"Holvast","year":"2017","journal-title":"PLoS One"},{"key":"2019081609500867900_key165-B156","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3899\/jrheum.101036","article-title":"Rheumatoid cachexia: what is it and why is it important?","volume":"38","author":"Rajbhandary","year":"2011","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B157","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3899\/jrheum.141629","article-title":"Does rheumatoid cachexia predispose patients with rheumatoid arthritis to osteoporosis and vertebral fractures?","volume":"42","author":"El Maghraoui","year":"2015","journal-title":"J Rheumatol"},{"key":"2019081609500867900_key165-B158","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"key":"2019081609500867900_key165-B159","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00198-015-3241-8","article-title":"Relationship of sarcopenia and body composition with osteoporosis","volume":"27","author":"He","year":"2016","journal-title":"Osteoporos Int"},{"key":"2019081609500867900_key165-B160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00198-012-2057-z","article-title":"Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men","volume":"24","author":"Verschueren","year":"2013","journal-title":"Osteoporos Int"},{"key":"2019081609500867900_key165-B161","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4065\/mcp.2010.0082","article-title":"Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women","volume":"85","author":"Adachi","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"2019081609500867900_key165-B162","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ageing\/afs194","article-title":"Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study","volume":"42","author":"Landi","year":"2013","journal-title":"Age Ageing"},{"key":"2019081609500867900_key165-B163","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/ageing\/afu065","article-title":"Pre-operative indicators for mortality following hip fracture surgery: a systematic review and meta-analysis","volume":"43","author":"Smith","year":"2014","journal-title":"Age Ageing"},{"key":"2019081609500867900_key165-B164","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/acr.22433","article-title":"Indicators of walking speed in rheumatoid arthritis: relative influence of articular, psychosocial, and body composition characteristics","volume":"67","author":"Lusa","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2019081609500867900_key165-B165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fnut.2014.00020","article-title":"Rheumatoid cachexia revisited: a metabolic co-morbidity in rheumatoid arthritis","volume":"1","author":"Masuko","year":"2014","journal-title":"Front Nutr"},{"key":"2019081609500867900_key165-B166","doi-asserted-by":"crossref","first-page":"439.e9","DOI":"10.1016\/j.jamda.2015.02.005","article-title":"Effects of an oral nutritional supplementation plus physical exercise intervention on the physical function, nutritional status, and quality of life in frail institutionalized older adults: the ACTIVNES Study","volume":"16","author":"Abizanda","year":"2015","journal-title":"J Am Med Dir Assoc"},{"key":"2019081609500867900_key165-B167","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10067-007-0765-0","article-title":"Comparison of group-based exercise versus home-based exercise in patients with ankylosing spondylitis: effects on Bath Ankylosing Spondylitis Indices, quality of life and depression","volume":"27","author":"Karapolat","year":"2008","journal-title":"Clin Rheumatol"},{"key":"2019081609500867900_key165-B168","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1586\/1744666X.2015.1067606","article-title":"The role of exercise in the management of rheumatoid arthritis","volume":"11","author":"Metsios","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"2019081609500867900_key165-B169","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jbspin.2016.10.003","article-title":"Nutrition and chronic inflammatory rheumatic disease","volume":"84","author":"Semerano","year":"2017","journal-title":"Joint Bone Spine"},{"key":"2019081609500867900_key165-B170","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.nut.2017.06.023","article-title":"Intake of \u03c9-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"45","author":"Gioxari","year":"2018","journal-title":"Nutr Burbank"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/5\/748\/28719624\/key165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T02:28:58Z","timestamp":1751682538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/5\/748\/5048710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":170,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,7,3]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key165","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2018,7,3]]}}}